Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Study Identifier:
ACH102-007
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Hepatitis
Study Drug
  • Drug: Sovaprevir
  • Drug: ACH-3102
  • Drug: Ribavirin
  • Drug: Placebo
Date
Apr 2013 - Nov 2013
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years
Requirements Information
Sex
Female & Male
Age
18 - 65 Years

Study Details

Medical Condition
  • Hepatitis
Study Drug
  • Drug: Sovaprevir
  • Drug: ACH-3102
  • Drug: Ribavirin
  • Drug: Placebo
Date
Apr 2013 - Nov 2013
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years years
Requirements Information

Protocol Summary

The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV) participants.

Trial Locations

No locations found.